Cotinine: Pharmacologically Active Metabolite of Nicotine and Neural Mechanisms for Its Actions
Authors:
Open Access
- 21 October 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 15
Abstract
Tobacco use disorder continues to be a leading public health issue and cause of premature death in the United States. Nicotine is considered as the major tobacco alkaloid causing addiction through its actions on nicotinic acetylcholine receptors (nAChRs). Current pharmacotherapies targeting nicotine’s effects produce only modest effectiveness in promoting cessation, highlighting the critical need for a better understanding of mechanisms of nicotine addiction to inform future treatments. There is growing interest in identifying potential contributions of non-nicotine components to tobacco reinforcement. Cotinine is a minor alkaloid, but the major metabolite of nicotine that can act as a weak agonist of nAChRs. Accumulating evidence indicates that cotinine produces diverse effects and may contribute to effects of nicotine. In this review, we summarize findings implicating cotinine as a neuroactive metabolite of nicotine and discuss available evidence regarding potential mechanisms underlying its effects. Preclinical findings reveal that cotinine crosses the blood brain barrier and interacts with both nAChRs and non-nAChRs in the nervous system, and produces neuropharmacological and behavioral effects. Clinical studies suggest that cotinine is psychoactive in humans. However, reviewing evidence regarding mechanisms underlying effects of cotinine provides a mixed picture with a lack of consensus. Therefore, more research is warranted in order to provide better insight into the actions of cotinine and its contribution to tobacco addiction.Keywords
Funding Information
- National Institutes of Health (DA044242)
This publication has 155 references indexed in Scilit:
- The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in ratsBiochemical Pharmacology, 2012
- Reward, Addiction, Withdrawal to NicotineAnnual Review of Neuroscience, 2011
- A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonistsBiochemical Pharmacology, 2009
- Desensitization of Nicotinic Acetylcholine Receptors as a Strategy for Drug DevelopmentThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Cotinine Selectively Activates a Subpopulation of α3/α6β2 Nicotinic Receptors in Monkey StriatumThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cellsNeuroToxicology, 2008
- Brain Uptake Kinetics of Nicotine and Cotinine after Chronic Nicotine ExposureThe Journal of Pharmacology and Experimental Therapeutics, 2005
- The potential role of cotinine in the cognitive and neuroprotective actions of nicotineLife Sciences, 2003
- Effect of nicotine on levels of extracellular amino acids in regions of the rat brain in vivoNeuropharmacology, 1993
- The enzyme “aldehyde oxidase” is an iminium oxidase. Reaction with nicotine Δ1′(5′) iminium ionBiochemical and Biophysical Research Communications, 1979